Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM8 | O00222 | 1/20 | 0.38 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.38 |
| ▸ | CES2 | O00748 | 1/20 | 0.35 |
| ▸ | CES1 | P23141 | 1/20 | 0.35 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.35 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.34 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.34 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | PPARA | Q07869 | 1/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.34 |
| ▸ | EEF2K | O00418 | 1/20 | 0.33 |
| ▸ | APP | P05067 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1519753 | 0.85 | FFAR1 (0.44) | GRM8GRM4CES2CES1PPARG | |
| SCHEMBL3286263 | 0.80 | CES2 (0.38) | GRM8GRM4CES2CES1AKR1C3 | |
| SCHEMBL8829766 | 0.76 | CES2 (0.40) | GRM8GRM4CES2CES1AKR1C3 | |
| SCHEMBL1147460 | 0.73 | PDPK1 (0.41) | GRM8GRM4CES2CES1AKR1C3 | |
| SCHEMBL3915984 | 0.72 | KMT2A (0.45) | AAK1MAPT | |
| SCHEMBL4659666 | 0.72 | KMT2A (0.45) | AAK1MAPT | |
| SCHEMBL17634288 | 0.72 | GSK3B (0.45) | CES2CES1AKR1C3AKR1C2PPARG | |
| SCHEMBL10564272 | 0.71 | GRB2 (0.49) | PPARGPPARADPP4DPP7 | |
| SCHEMBL1519829 | 0.71 | FFAR1 (0.40) | AAK1FFAR1APPMAPTDPP4 | |
| SCHEMBL4969230 | 0.71 | CES2 (0.37) | CES2CES1AAK1AKR1C3AKR1C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1720855-A4 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORP (US) | 2008-12-17 | — | — | EP | disclosed |
| US-20070185152-A1 | Inhibitors of akt activity | SMITHKLINE BEECHAM CORPORATION | 2007-08-09 | — | — | US | disclosed |
| EP-1720855-A1 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2006-11-15 | — | — | EP | disclosed |
| WO-2005085227-A1 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2005-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185152-A1 | Inhibitors of akt activity | AKT1, AKT1S1, AKT2 | GRM8 4021/4885GRM4 4332/4885CES2 4333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.